BCHT(SH:688276) Zheng Quan Shi Bao Wang·2025-10-09 09:32Core Viewpoint - The approval of the combined vaccine for whooping cough, diphtheria, tetanus, and Hib by the National Medical Products Administration represents a significant advancement for the company, potentially enhancing its product offerings and market position in the vaccine sector [1][2]. Group 1: Vaccine Development - The newly approved combined vaccine can simultaneously prevent whooping cough, diphtheria, tetanus, and Hib infections, targeting infants aged 2 months and older [1]. - The combined vaccine offers the advantage of "one shot for multiple protections," which can reduce the number of injections required, lower vaccination costs, and improve vaccination coverage [1]. - The combined vaccine is based on the company's existing vaccines, including the acellular whooping cough vaccine and the lyophilized Hib vaccine, which together enhance compliance among infants [1]. Group 2: Impact on Company - If the combined vaccine successfully completes clinical trials and receives market approval, it will enhance the company's vaccine development pipeline and contribute to the overall growth of its main business [2]. - The company has previously received approval for other vaccines, including a recombinant shingles vaccine and an influenza virus split vaccine, indicating a robust pipeline of vaccine candidates [2]. - The company reported a significant increase in R&D investment, amounting to 98.2 million yuan, which represents 34.47% of its revenue, compared to 13.83% in the previous year [3].